WANG Hai-rong,ZHU Wei-guo,QIN Shan-shan,GUO Jia-ni,WANG Hai-dong,LI Tao,TAO Guang-zhou,JI Fu-zhi,ZHOU Xi-lei,HAN Ji-hua,YU Chang-hua.A randomized, controlled study of different chemotherapy regimens combined with postoperative radiotherapy for patients with high-risk early stage cervical cancer[J].Chinese Journal of Radiological Medicine and Protection,2013,33(1):50-54
A randomized, controlled study of different chemotherapy regimens combined with postoperative radiotherapy for patients with high-risk early stage cervical cancer
Received:August 13, 2012  
DOI:10.3760/cma.j.issn.0254-5098.2013.01.013
KeyWords:Early stage cervical cancer  Concurrent chemoradiotherapy  Overall survival rate  Recurrence-free survival rate
FundProject:江苏省淮安市科技支撑计划(HAS2010030)
Author NameAffiliationE-mail
WANG Hai-rong First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
ZHU Wei-guo First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China jshazwg@126.com 
QIN Shan-shan First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
GUO Jia-ni First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
WANG Hai-dong First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
LI Tao First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
TAO Guang-zhou First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
JI Fu-zhi First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
ZHOU Xi-lei First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
HAN Ji-hua First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
YU Chang-hua First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China  
Hits: 3430
Download times: 2663
Abstract::
      Objective To investigate whether docetaxel plus cisplatin combined with radiotherapy(TP-R) compared with cisplatin-only combined radiotherapy(C-R) could increase overall survival and recurrence-free survival on patients with high-risk early stage cervical cancer.Methods Eligible high-risk patients with stage Ⅰb and Ⅱa cervical cancer were randomly assigned to C-R and TP-R group. The external irradiation dose was 46-54 Gy, following 12-24 Gy of intracavitary brachytherapy. In C-R group, chemotherapy regimens consisted of cisplatin 30 mg/m2 (weekly, with 5 cycles). In TP-R group, chemotherapy regimens consisted of cisplatin 25 mg/m2 and of docetaxel 25 mg/m2 (weekly, with 5 cycles). Results A total of 285 patients entered final analysis. There were 140 cases in C-R group and 145 in TP-C group, respectively. The 5-year overall survival rate was 74.3% in C-R group and 82.8% in TP-R group(P>0.05). The hazard ratio for death on TP-R group was 0.65(95%CI: 0.39-1.09). The 5-year recurrence survival rates were 69.3% in C-R group and 79.3% in TP-R group(P>0.05), respectively. And the hazard ratio for death on TP-R group was 0.64(95%CI: 0.40-1.03). Recurrence rates were similar in two groups(P>0.05).Rate of ≥ grade 3 adverse events was higher in TP-R group(χ2=6.88, P<0.05). Conclusions Docetaxel plus cisplatin combined with radiotherapy fails to increase overall survival rates compared with cisplatin-only combined with radiotherapy for patients with high-risk stageⅠb and Ⅱa cervical cancer, though there is a trend to increase recurrence-free survival rates.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:9056527  On-line:0

v
Scan QR Code
&et=3931F69C5BAC493D628D7C3463C33D6E2CC8ED4ED4C289AB932A6A02763E52F4DE40636D7EE77BD14F3F01936189830E0406B9F9FFE04565563F5291DC9AEC5E0B7827A5B5EE7B1624BA81B7B66B1AD4A626F30C1531C6028794E406E4B6AC25BAA249E89702A2E4556E2A729425029157FD27B23A19495D0C6B2A54FFDDBAA34009201678FB67C229353E73FBE387758096592DDBEA6F0ED1FA6105B4227DD66701F4624BBB908A&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=FF7AA908D58E97FA&aid=08F5EC0AA8616491E4E2DCA4FF4ABFC1&vid=&iid=CA4FD0336C81A37A&sid=771152D1ADC1C0EB&eid=318E4CC20AED4940&fileno=20130113&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="FF7AA908D58E97FA"; var my_aid="08F5EC0AA8616491E4E2DCA4FF4ABFC1";